Single-agent bortezomib, a potent, selective and reversible inhibitor of the 26S proteasome, has demonstrated clinical efficacy in relapsed and refractory mantle cell lymphoma (MCL). Objective response is achieved in up to 45% of the patients; however, complete remission rates are low and duration of response proved to be short. These limitations may be overcome by combining proteasome inhibition with conventional chemotherapy. Here we present two case reports and in vitro data suggesting synergistic efficacy of bortezomib combined with cytarabine in MCL. Interestingly, efficacy in vitro correlated with sequence of treatment, indicating that pretreatment with cytarabine, followed by proteasome inhibition, may be the preferred approach.
Introduction
The ubiquitin-proteasome pathway is essential for maintaining intracellular protein homeostasis and represents a valid target for the treatment of malignant disease. 1 Various oncogenes and regulatory proteins for cell cycle progression and apoptosis are processed by this pathway. 2 Bortezomib is a potent, selective and reversible inhibitor of the proteasome with demonstrated efficacy in relapsed multiple myeloma. 3, 4 Single-agent bortezomib demonstrated clinical activity in several other hematologic malignancies 5 with especially encouraging results in relapsed or refractory mantle cell lymphoma (MCL). [6] [7] [8] Objective response is achieved in 29-45% of MCL patients; however, complete remission rates are low and median duration of response short. These limitations may be overcome by combining bortezomib with conventional chemotherapy. 9, 10 Feasibility has been demonstrated for liposomal doxorubicin. 11 We present two case reports and in vitro data suggesting a sequence-dependent synergy of bortezomib and cytarabine in MCL.
Case report 1
A 67-year-old man with relapsed stage IV MCL presented with progressive bilateral leg edema caused by extensive inguinal, iliac and paraaortic lymphadenopathy. Previous treatment consisted of CHOP (cyclophosphamide, vincristine, doxorubicin and prednisone), 12 R-FCM (rituximab, fludarabine, cyclophosphamide, and mitoxantrone) 13 and gemcitabine/oxaliplatin with all relapses occurring within 1 year. No response was seen after radioimmunotherapy with rituximab/ 90 Y-ibritumomabtiuxetan 5 months earlier. Salvage therapy was started with single-agent bortezomib 1.3 mg/m 2 given intravenously twice weekly for 2 consecutive weeks, followed by a 1-week rest period. Because of progressive lymphadenopathy at week 5, treatment was changed to a combination regimen consisting of bortezomib (1.5 mg/m 2 , days 1 and 4) and cytarabine (1000 mg/m 2 as a 3-h infusion on days 2 and 3) applied in 3-week intervals. After two cycles, the leg edema and lymphadenopathy improved dramatically, and a very good partial response was confirmed by computer tomography (CT) scanning (Figure 1a and b) . Because of NCI/CTC grade 4 neutropenia after cycle 2, the dose of cytarabine was reduced to 75% and granulocyte-colony-stimulating factor (G-CSF) support was initiated. Importantly, there was no infectious complication and only cycle 4 had to be delayed for 1 week. Because of NCI/ CTC grade 3 sensory peripheral neuropathy after cycle 2, bortezomib was omitted during the subsequent two cycles with polyneuropathy gradually improving; the hematologic toxicity did not differ significantly after bortezomib was held. Except for alopecia, there was no additional significant non-hematological toxicity. Meanwhile, 11 months (343 days) after initiation of combination therapy, the patient suffered from systemic progression and was started on a bendamustin-containing regimen.
Case report 2
A 63-year-old woman with relapsed stage IV MCL presented with progressive abdominal lymphadenopathy and reappearance of extensive watery diarrhea, attributable to exacerbation of colonic infiltration, confirmed by colonoscopy after 10 cycles of single-agent bortezomib therapy (1.3 mg/m 2 intravenous, days 1, 4, 8, 11, every 3 weeks). Four years earlier, the disease was diagnosed with colonic polyposis and infiltration of the stomach, the nasopharynx, the right lacrimal gland and bone marrow involvement. Previous treatment consisted of CHOP followed by interferon maintenance, 12 R-FCM 13 and radioimmunotherapy with rituximab/ 90 Y-ibritumomab-tiuxetan. The best response consisted of partial remission, and duration of response declined from initially observed 21 months with every consecutive line of treatment. Single-agent bortezomib treatment resulted in a decreased frequency of diarrhea by cycle 4, which however, failed by cycle 10. Treatment was changed to the combination regimen, consisting of bortezomib (1.5 mg/m 2 , days 1 and 4) and cytarabine (1000 mg/m 2 as a 3-h infusion on days 2 and 3), applied in 4-week intervals with rituximab added on day 0 (375 mg/m 2 ). Because of NCI/CTC grade 1 sensory peripheral neuropathy, the dose of bortezomib was reduced to 1.0 mg/m 2 during cycles 2-4. The diarrhea improved rapidly and disappeared subsequently. After two and four cycles, a complete disappearance of pathological lymphadenopathy was confirmed by CT scanning (Figure 1c and d) . Endoscopically, the polypoid lesions decreased substantially however, residual MCL infiltration was seen on biopsy specimen. A partial remission was diagnosed and no further treatment was applied to the asymptomatic patient. NCI/CTC grade 3/4 toxicity consisted mainly of myelotoxicity, with neutropenia requiring G-CSF support and one episode of neutropenic fever requiring empiric antibiotic treatment. There was no treatment delay and no dose reduction of cytarabine. Meanwhile, the patient has remained in documented ongoing remission for more than 7 months (233 days) after initiation of combination treatment with no diseaserelated symptoms.
Materials and methods

Cell culture and reagents
Established MCL cell lines consisted of Granta519, HBL-2 and Jeko-1; the T-ALL cell line Jurkat was used as hematologic control cell line; all established cell lines were obtained from DSMZ (German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany). After having obtained informed consent, primary MCL cells were collected from peripheral blood or bone marrow aspiration and purified by magnetic cell sorting for CD19 according to the manufacturer's protocol (MACS, Miltenyi-Biotec, Bergisch-Gladbach, Germany). Cells were cultured in RPMI 1640 culture medium supplemented with 10-20% heat-inactivated fetal calf serum (371C, humified atmosphere containing 5% carbon dioxide) and incubated with bortezomib (Velcade, Janssen-Cilag, Neuss, Germany) alone, cytarabine (Ara-Cell, Cell Pharm, Hannover, Germany) alone, or in combination of both.
Proliferation assay
Cells were seeded at a density of 5 Â 10 5 /ml in the absence or presence of bortezomib (25 nM). Cells were counted in a hematocytometer, and viability of cells was assessed by Trypan blue exclusion test (Gibco, Invitrogen, Karlsruhe, Germany) at 0, 24, 48 and 96 h of treatment.
Apoptosis assay
Cells were washed and stained with Annexin V-PE/7-AAD in accordance with the manufacturer's protocol (BD Biosciences, Heidelberg, Germany) and subjected to flow cytometry (BD FACS Calibur, BD Biosciences, Palo Alto, CA, USA). Apoptosis rate was calculated as follows: 
Cell viability assay and determination of Chou and Talalay's combination index
Cell viability correlates with the activity to metabolize the tetrazolium salt WST-1 to a water-soluble formazan dye, which is measured spectrophotometrically. Cells were seeded at a density of 1 Â 10 6 /ml in a 96-well microplate in triplicate (100 000 cells/well) and the assay was performed according to the manufacturer's protocol (Roche Applied Science, Mannheim, Germany). The half maximal inhibitory concentration (IC 50 ) was used for calculation of Chou and Talalay's combination index (CI 50 ) applying CalcuSyn Software (Biosoft, Cambridge, UK) as described previously.
14 This index allows identification of antagonistic (CI 50 41.3), additive (CI 50 ¼ 170.3) or synergistic (CI 50 o0.7) efficacy of combination treatment by considering cell viability curves determined after 12 and 24 h of treatment with cytarabine alone, bortezomib alone or in combination (synchronous and sequential incubation) of both, respectively.
Statistical analysis
A two-sided Student's t-test was applied when indicated. (Figure 2b ), this indicates that either higher concentrations or longer incubation times are required for bortezomib single-agent or combination therapy to induce cytotoxicity in the non-MCL cell line Jurkat. Strikingly, all four highly purified primary MCL samples were remarkably more sensitive to coincubation of bortezomib and cytarabine than would have been expected based on the efficacy of each monotherapy, estimated by cumulative probability (Figure 3) .
Results
At
Impact of sequence of treatment on efficacy was investigated in established MCL cell lines by determination of CI 50 . Interestingly, in all MCL cell lines, preincubation with cytarabine for 12 h, followed by addition of bortezomib for another 12 h, revealed synergistic activity (CIo0.770.05-0.08) based on cell viability curves, whereas incubation conversely resulted in antagonism in HBL-2 and Jeko-1 (Table 1) .
Discussion
Our in vitro data not only confirm antilymphoma activity of bortezomib especially in MCL, but strongly suggest enhanced efficacy of bortezomib if combined with cytarabine. Interestingly, efficacy correlated with the sequence of treatment, indicating superiority of pretreatment with cytarabine, followed by proteasome inhibition.
Cytarabine is one of the most effective drugs used in the treatment of hematologic malignancies including MCL either as monotherapy 15 or in combination with other cytostatic agents. after incubation with cytarabine (1 mg/ml), bortezomib (10 nM) or both for 24 h. Cells were collected from peripheral blood or bone marrow aspiration and purified by CD19 þ MACS (495% of cells with double staining for CD5 and CD20). 'Expected' efficacy was calculated by applying cumulative probability based on efficacy of each monotherapy.
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After conversion to its triphosphate-derivative, ara-cytidine triphosphate (CTP), it interferes with DNA polymerases and incorporates into the genome mainly during DNA replication, thereby affecting the structural integrity of DNA, that is, stalling of replication fork and chain termination. DNA damage sensors (e.g., ATM, ATR and DNA-PK) and transducers (e.g., p53, JNK, Bax, Bak) activate checkpoint pathways that arrest cell cycle progression and, if survival mechanisms are overwhelmed, signalling pathways are activated, initiating the apoptotic pathway. 17 Mitochondrial release of cytochrome c and other proapoptotic molecules (e.g., Smac/DIABLO, 18 Omi/HtrA2 19 ) promotes the formation of the apoptosome, a high-molecularweight-complex consisting of Apaf-1, dATP and procaspase-9. Recruited caspase-9 activates effector caspases (e.g., caspase-3 and 7), which execute the cell death program.
Considering the abundant presence and necessity of proteasome activity in eukaryotic cells, bortezomib displays surprisingly little toxicity in clinical practice, with mild thrombocytopenia, neuropathy and diarrhea being most common. 5 Little is known about downstream events caused by proteasome inhibition. Gene profiling studies demonstrate overexpression of Nuclear factor-kappa B (NF-kB)-dependent gene products in MCL, indicating constitutive activation of the NF-kB signalling pathway. 20 NF-kB has been implicated in blocking apoptosis, promoting cell proliferation and mediating treatment resistance. 21 Activation of NFkB requires phosphorylation of its inhibitor kinase B (IkB), leading to polyubiquitinylation and degradation by the proteasome. Until recently, antineoplastic activity of proteasome inhibitors has been largely attributed to inhibition of NF-kB activation. 22 However, alternative downstream mechanisms of proteasome inhibition, such as generation of reactive oxygen species (ROS) and upregulation of BH3-only mitochondrial protein Noxa, have been suggested. 23 Noxa not only contributes to apoptosis by disrupting outer mitochondrial membrane integrity but also binds to Mcl-1, 24 thereby displacing proapoptotic Bak. 25 Apart from Noxa and IkB, impaired proteasome activity also leads to accumulation of several other crucial cellular proteins such as p21, p27, p53 23 and Smac/DIABLO. 19 Consequently, proteasome inhibition in cells that have previously been exposed to cytarabine might well further enhance chemotherapy-induced increased levels of the aforementioned proapoptotic molecules, thereby promoting apoptosis. On the other hand, it has been shown that in late-stage apoptotic cells, effector caspases irreversibly inactivate proteasome activity by cleaving three subunits of the 19S particle. 19 These data suggest that the timing of proteasome inhibition may be important to augment cytotoxicity of conventional chemotherapy.
We Our heavily pretreated patients with relapsed advanced-stage MCL had progressive lymphadenopathy after 5 and 30 weeks of single-agent bortezomib treatment. Owing to the relatively short course of bortezomib treatment in case report 1 and the transient response in case report 2, it remains speculative whether these lymphomas can be considered completely resistant to bortezomib. However, because of progressive clinical symptoms, a combination treatment consisting of bortezomib and cytarabine was initiated. This particular treatment schedule was based primarily on clinical considerations as preliminary experience with the DA-EPOCH regimen defined the maximal-tolerated dose for bortezomib (1.5 mg/m 2 applied on days 1 and 4) (Dunleavy et al., Blood 2004; 104: 389a, abstract 1385). As both patients developed sensory polyneuropathy, probably also because previous treatment regimens included well-known neurotoxic agents such as vincristine, oxaliplatin and bortezomib itself, bortezomib had to be stopped after cycle 2 in patient 1, and dose was reduced in patient 2. Despite the fact that both patients never failed cytarabine-containing regimens before, this report is the first to demonstrate that combining proteasome inhibition with high-dose cytarabine is feasible and highly active in MCL, thus warranting further testing in clinical trials. 
